Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-07-03
2007-07-03
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S200100, C424S234100, C424S093200, C424S093400, C424S192100, C424S250100, C424S093480, C536S023700, C435S230000, C435S071100, C435S069300, C435S069700
Reexamination Certificate
active
08461651
ABSTRACT:
Outer-membrane vesicles, Class 1 outer membrane proteins ofNeisseria meningitidis,fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.
REFERENCES:
patent: 4271147 (1981-06-01), Helting et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4673574 (1987-06-01), Anderson
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 4762713 (1988-08-01), Anderson
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5691449 (1997-11-01), Paradiso et al.
patent: 5736361 (1998-04-01), Carbonetti et al.
patent: 5780261 (1998-07-01), Kontinen et al.
patent: 6130082 (2000-10-01), Majarian et al.
patent: 6348332 (2002-02-01), Carbonetti et al.
patent: 0 011 243 (1980-05-01), None
patent: 0 090 660 (1983-10-01), None
patent: 0 109 688 (1984-05-01), None
patent: 0 145 359 (1985-01-01), None
patent: 0 102 401 (1986-05-01), None
patent: 0 182 401 (1986-05-01), None
patent: 0 301 992 (1989-02-01), None
patent: 0 351 604 (1990-01-01), None
patent: 0 372 501 (1990-06-01), None
patent: 0 449 958 (1991-10-01), None
patent: 0474313 (1992-03-01), None
patent: 64-29321 (1989-01-01), None
patent: PT 87935 (1988-08-01), None
patent: CN 1030443 (1989-01-01), None
patent: WO 89/04873 (1989-06-01), None
patent: WO 89/10967 (1989-11-01), None
patent: WO 90/06696 (1990-06-01), None
patent: WO 94/08021 (1994-04-01), None
Illustrated Stedman's Medical Dictionary, 24th Edition, Williams & Wilkins, Baltimore/London, p. 1120, 1983.
Bowie et al. Science 247: 1306-1310, 1990.
Burgess et al. J. Cell Biol. 111: 2129-2138, 1990.
Lazar et al. Mol. Cellular Biol. 8: 1247-1252, 1988.
Zhou et al. Mol. Microbiol. 23: 799-812, 1997.
Maedland et al. Mol. APMIS 97: 774-780, Sep. 1989.
Maiden et al. Mol. Microbiol. 5: 727-736, 1991.
Carbonetti et al. PNAS 85: 6841-6845, Sep. 1988.
McGuinness et al. J. Exp. Med. 171: 1871-1882, Jun. 1990.
Wiertz et al. Eleventh American Peptide Symposium. La Jolla, CA, Jul. 9-4, 1989, pp. 731-732.
Sambrook et al. Molecular Cloning: A Laboratory Manual. Second Edition, Cold Spring Harbor, pp. 17.1-17.44, 1989.
Illustrated Stedman's Medical Dictionary, 24th Edition, p. 1051, 1982.
Palker et al. J. Immunology 142: 3612-3619, 1989.
McCarvil et al. Mol. Microbiol. 10: 203-213, 1993.
White et al. Mol. Microbiol. 4: 769-776, 1990.
Beuvery, E. C., et al., “Preparation and Physiocochemical and Immunological Characterization of Polysaccharide-Outer Membrane Protein Complexes ofNeisseria meningitidis,” Infection and Immunity,40(1):369-380 (1983).
Jiskoot, W., et al., “Immunogenic Activity of Gonococcal Protein I in Mice with Three Different Lipoidal Adjuvants Delivered in Liposomes and in Complexes,”Infection and Immunity,54(2):333-338 (1986).
Wang, L. Y., and Frasch, C. E., “Development of aNeisseria meningitidisGroup B Serotype 2b Protein Vaccine and Evaluation in a Mouse Model,”Infection and Immunity,46(2):408-414 (1984).
Teerlink, T., et al., “Synergistic Effect of Detergents and Aluminium Phosphate on the Humoral Immune Response to Bacterial and Viral Membrane Proteins,”Vaccine,5(4):307-314 (1987).
Gregoriadis, G., et al., “Liposomes as Immunological Adjuvants: Antigen Incorporation Studies,”Vaccine,5(2) :145-151 (1987).
Tsai, C-M., and Frasch, C. E., “Chemical Analysis of Major Outer Membrane Proteins ofNeisseria meningitidis:Comparison of Serotypes 2 and 11,”Journal of Bacteriology,141(1) :169-176 (1980).
Tsai, C-M., et al., “Five Structural Classes of Major Outer Membrane Proteins inNeisseria meningitidis,” J. Bacteriol., 146(1) :69-78 (1981). (FromChem. Abstracts, 1981, 94, Abstract No. 205111z).
Barlow, A. K., et al., “Molecular Cloning and Expression ofNeisseria meningitidisClass 1 Outer Membrane Protein inEscherichia coliK-12,”Infection and Immunity,55(11) :2734-2740 (1987).
Wedege, E., et al., “Restoration of Antibody Binding to Blotted Meningococcal Outer Membrane Proteins Using Various Detergents,”Journal of Immunological Methods,113:51-59 (1988).
Abdillahi, H. and Poolman, J. T., “Definition of Meningococcal Class 1 OMP Subtyping Antigens by Monoclonal Antibodies,”Microbiol. Immunol.,47(3) :139-144 (1988). (FromBiological Abstracts,1989, 87, Abstract No. 115445).
Poolman, J. T., et al., “Purification, Cyanogen Bromide Cleavage, and Amino Terminus Sequencing of Class 1 and Class 3 Outer Membrane Proteins of Meningococci,”Infection and Immunity,57(3) :1005-1007 (1989).
Barlow, A. K., et al., “The Class-1 Outer Membrane Protein ofNeisseria—Meningitidis:Gene Sequence and Structural and Immunological Similarities to Gonococcal Porins,”Molecular Microbiology,3(2) :131-139 (1989).
Poolman, J. T., “Immunogenicity of Meningococcal Antigens as Detected in Patient Sera,”Infection and Immunity,40(1) :398-406 (1983).
Frasch, C. E., et al., “Immunogenicity and Clinical Evaluation of Group BNeisseria meningitidisOuter Membrane Protein Vaccines.” InSeminars in Infectious Disease, vol. IV: Bacterial Vaccines,J. B. Robbins, et al., eds. (NY: Thieme-Stratton Inc.), pp. 263-267 (1982).
Mäkelä, P. H., et al., “Porins: The Major Outer Membrane Proteins of Enteric Bacteria as Protective Antigens.” InSeminars in Infectious Disease, vol. IV: Bacterial Vaccines,J. B. Robbins, et al., eds. (NY: Thieme-Stratton Inc.), pp. 360-365 (1982).
Newton, S. M. C., et al., “Immune Response to Cholera Toxin Epitope Inserted inSalmonella Flagellin,” Science,244:70-72 (1989).
Bessler, W. G., et al., “Specific Antibodies Elicited by Antigen Covalently Linked to a Synthetic Adjuvant,”Immunobiol.,170:239-244 (1985).
Lerner, R. A., “Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity,”Nature,299:592-596 (1982).
Lowell, George H., et al., “Peptides Bound to Proteosomes Via Hydrophobic Feet Become Highly Immunogenic Without Adjuvants,”Journal of Experimental Medicine,167:658-663 (1988).
Saukkonen, K., et al, “Protective Efficacy of Monoclonal Antibodies to Class 1 and Class 3 Outer Membrane Proteins ofNeisseria meningitidisB:15:P1.16 in Infant Rat Infection Model: New Prospects for Vaccine Development,”Microbial Pathogensis,3:261-267 (1987).
Mandrell, R.E., et al., “Human Immune Response to Meningococcal Outer Membrane Protein Epitopes After Natural Infection or Vaccination,”Infection and Immunity,57:1590-1598 (1989).
Hirama, M., “Cloning of cDNAs with Vectors Permitting Expression in Host Cells.” InImmunological Methods, vol. III,Lefkovits, I. and Pernis, B., eds. (Orlando: Academic Press, Inc.), p. 52 (1985).
Wiertz, E.J.H.J., et al., “Human T-Cell Epitope Mapping of the Meningococcal Class 1 Outer Membrane Protein.” Symposium on Immunogenicity, Steamboat Springs, CO, Jan. 21-28, 1989. (FromBiological Abstracts/RRM,BR36:126147, Abstract No. 89:258923.)J. Cell. Biochem.suppl. 0 (13 Part A). 1989. 326.
International Search Report from PCT Application No. 89/05678 (Publication No. WO 90/06696, filed Dec. 19, 1989.
Wedege, E. and L. Oddvar Frohølm, “Human Antibody Response to a Group B Serotype 2a Meningococcal Vaccine Determined by Immunoblotting,”Infection and Immunity,51(2):571-578 (1986).
Frasch, C.E., et al., “Immune Responses of Adults and Children to Group BNeisseria meningitidisOuter Membrane Protein Vaccines,”Bacterial Vaccines,262-272, Academic Press (1988).
Beuvery, E.C., et al., “Characteristics of an Alternative Meningococcal Type 15 (P1. 16) Outer Membrane Protein Vaccine,”Antonie van Leeuwenhoek 52:232-235 (1986). International Symposium—Meningococcal Disease in N.W. Europe.
Poolman, J.T., et al., “Comparison of Meningococcal Outer Membrane Protein Vaccines Solubilized with Detergent or C Polysaccharide,”Antonie van Leeuwenhoek,53:413-419 (1987).
Wiertz, E.J.H.J., et al., ȁ
Clarke Ian Nicholas
Heckels John Edward
Hoogerhout Peter
Paradiso Peter R.
Poolman Jan T.
Devi S.
Hamilton Brook Smith & Reynolds P.C.
Wyeth Holdings Corporation
LandOfFree
Recombinant microorganism expressing meningococcal class 1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant microorganism expressing meningococcal class 1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant microorganism expressing meningococcal class 1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774364